Based on the results from the ToGA trial, the HercepTestTM was approved by FDA in 2010 as a companion diagnostic for trastuzumab for treatment of HER2 positive patients with metastatic gastric or gastroesophageal junction adenocarcinoma, as shown in Figure 1. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.